Sign in
TerminatedNo phase

Digital Remote Home Monitoring for Heart Failure

Key facts

Who runs it
University of Texas Southwestern Medical Center
Where
Dallas, United StatesSee the 2 sites
Trial code
Status
Terminated
People taking part
15 people enrolled
Started
13 Dec 2024
Ended
30 Nov 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Biofourmis Digital Platform
Record updated
18 February 2026
Why it stopped
Due to sponsor request for poor enrollment

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • ≥18-year-old adults with a clinical diagnosis of heart failure AND a left ventricular ejection fraction ≤40% by transthoracic echocardiogram or cardiac MRI within 12 months prior to enrollment

Who cannot take part

  • Recent or home inotropic therapy, or heart transplant evaluation
  • End-stage renal disease, receiving dialysis or eGFR ≤30 mL/min/1.73m2
  • Patients who are pregnant
  • Patients who do not have a smartphone or access to the Internet
  • Prisoners or refugees
  • Patients who are homeless or have unstable housing
  • Unable or unwilling to consent or use study related materials
  • On-going cocaine, methamphetamine, opioid, alcohol, or other illicit substance abuse as determined by the study PI
  • Not fluent in English or Spanish
  • Students or trainees at UT-Southwestern or Parkland Health System
  • Enrolled or considering hospice
  • Survival anticipated <6 months
  • Non-Texas resident

Where in United States

  • Parkland Health & Hospital SystemDallas, United States
  • UT Southwestern Medical CenterDallas, United States

About the trial

What the trial wants to find out

We will enroll 150 adult participants with systolic heart failure into the ADHERE-HF trial. The study will randomize participants in a 1:2 fashion to usual care or usual care plus the American Heart Association's Digital Solution for 90 days. This wearable device and careplan package is hypothesized to improve rates of guideline directed heart failure medical care for participants.

The 2 groups in the trial

  • DeviceTreatment being tested

    Participants will receive usual care or usual care plus the American Heart Association's Digital Solution in patients with HFrEF. The Solution is a combination of the AHA/CHTI HF CarePlans and Education Content, delivered through and combined with the Biofourmis Platform.

    Treatment: Biofourmis Digital Platform

  • Routine CareNo study treatment, for comparison

    Routine care for heart failure management

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
American Heart Association Digital Home Remote Monitoring for Heart Failure
Record updated
18 February 2026